Hahka-Kemppinen M - Search Results

1

Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma.

Pyrhönen S, Hahka-Kemppinen M, Muhonen T, Nikkanen V, Eskelin S, Summanen P, Tarkkanen A, Kivelä T. Pyrhönen S, et al. Cancer. 2002 Dec 1;95(11):2366-72. doi: 10.1002/cncr.10996. Cancer. 2002. PMID: 12436444 Free article. Clinical Trial.

2

The prognostic role of CD4+ and CD8+ lymphocytes during chemoimmunotherapy in metastatic melanoma.

Hernberg MM, Hahka-Kemppinen MH, Pyrhönen SO. Hernberg MM, et al. Among authors: hahka kemppinen mh. Melanoma Res. 2004 Dec;14(6):493-500. doi: 10.1097/00008390-200412000-00009. Melanoma Res. 2004. PMID: 15577320

3

High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma.

Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Kähäri VM, Pyrhönen S. Nikkola J, et al. Int J Cancer. 2002 Feb 1;97(4):432-8. doi: 10.1002/ijc.1636. Int J Cancer. 2002. PMID: 11802203 Free article. Clinical Trial.

4

Immunohistochemically detectable bcl-2 expression in metastatic melanoma: association with survival and treatment response.

Vlaykova T, Talve L, Hahka-Kemppinen M, Hernberg M, Muhonen T, Collan Y, Pyrhönen S. Vlaykova T, et al. Oncology. 2002;62(3):259-68. doi: 10.1159/000059574. Oncology. 2002. PMID: 12065874

5

A prognostic model and staging for metastatic uveal melanoma.

Eskelin S, Pyrhönen S, Hahka-Kemppinen M, Tuomaala S, Kivelä T. Eskelin S, et al. Cancer. 2003 Jan 15;97(2):465-75. doi: 10.1002/cncr.11113. Cancer. 2003. PMID: 12518371 Free article.

6

Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma.

Vuoristo MS, Hahka-Kemppinen M, Parvinen LM, Pyrhönen S, Seppä H, Korpela M, Kellokumpu-Lehtinen P. Vuoristo MS, et al. Among authors: hahka kemppinen m. Melanoma Res. 2005 Aug;15(4):291-6. doi: 10.1097/00008390-200508000-00010. Melanoma Res. 2005. PMID: 16034308 Clinical Trial.

7

A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma.

Pyrhönen S, Hahka-Kemppinen M, Muhonen T. Pyrhönen S, et al. J Clin Oncol. 1992 Dec;10(12):1919-26. doi: 10.1200/JCO.1992.10.12.1919. J Clin Oncol. 1992. PMID: 1280673

8

Decreasing CD4/CD8 ratio during prolonged four-drug chemotherapy plus interferon treatment for metastatic melanoma.

Muhonen T, Hahka-Kemppinen M, Pakkala S, Pyrhönen S. Muhonen T, et al. J Immunother Emphasis Tumor Immunol. 1994 Jan;15(1):67-73. doi: 10.1097/00002371-199401000-00009. J Immunother Emphasis Tumor Immunol. 1994. PMID: 7509188

9

Response of subcutaneous and cutaneous metastases of malignant melanoma to combined cytostatic plus interferon therapy.

Hahka-Kemppinen M, Muhonen T, Virolainen M, Jekunen A, Asko-Seljavaara S, Pyrhönen S. Hahka-Kemppinen M, et al. Br J Dermatol. 1995 Jun;132(6):973-7. doi: 10.1111/j.1365-2133.1995.tb16958.x. Br J Dermatol. 1995. PMID: 7544996

10

The CD4+/CD8+ ratio as a prognostic factor in patients with metastatic melanoma receiving chemoimmunotherapy.

Hernberg M, Muhonen T, Turunen JP, Hahka-Kemppinen M, Pyrhönen S. Hernberg M, et al. J Clin Oncol. 1996 May;14(5):1690-6. doi: 10.1200/JCO.1996.14.5.1690. J Clin Oncol. 1996. PMID: 8622089

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

33 results

Search Page